Christopher J. Molineaux

Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome

Susan D. Demo, Christopher J. Kirk, Monette Aujay et al. · Cancer Research · 2007 · 675 citations · Full text

Medicine, Oncology, Pharmacology +13

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

Owen A. O’Connor, A. Keith Stewart, Marcy K. Vallone et al. · Clinical Cancer Research · 2009 · 301 citations · Full text

Medicine, Oncology, Pharmacology +15

Dynorphin-A-(1-8) Is Contained Within Vasopressin Neurosecretory Vesicles in Rat Pituitary

Mark H. Whitnall, Harold Gainer, Brian M. Cox et al. · Science · 1983 · 206 citations

Life Sciences, Neurobiology, Physiology +17

Development of C5a receptor antagonists. Differential loss of functional responses.

Zenon Konteatis, Salvatore Siciliano, Gail Van Riper et al. · The Journal of Immunology · 1994 · 152 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma

Melissa Alsina, Suzanne Trudel, Richard R. Furman et al. · Clinical Cancer Research · 2012 · 145 citations

Medicine, Clinical Pharmacokinetics, Pharmacology +15